Biochem/physiol Actions

Target IC₅₀: 6, 3, 229, and >300 →M for NR2C, NR2D, NR2A, and NR2B, respectively.

Primary TargetNMDA receptors

General description

A noncompetitive and voltage-independent antagonist selective for NR2C/D containing NMDA receptors (IC₅₀ = 6, 3, 229, and >300 µM for NR2C, NR2D, NR2A, and NR2B, respectively). Inhibition on NR2C/D containing NMDA receptors is glutamate-binding, but not glycine-binding, dependent. Represents a new class of noncompetitive subunit-selective NMDA receptor antagonists. With more than 100-fold selectivity for recombinant NMDA receptors over AMPA and kainate receptors.

Legal Information

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Other Notes

Mayer, M., et al. 2013. Annu. Rev. Physiol.75, 1.r>Hansen, K., 2011. J. Neurosci.9, 3650.r>Mosley, C., et al. 2010. J. Med. Chem.53, 5476.

Packaging

5 mg in Glass bottle

Preparation Note

Slight warming is required for complete solubilization.

Reconstitution

Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.

Warning

Toxicity: Standard Handling (A)